All Drug Targets articles – Page 29
-
ArticleTargeted protein degradation: turning undruggable targets into druggable targets
Targeted protein degradation (TPD) is a cutting-edge approach in drug discovery that offers a more precise and efficient way to alter cellular pathways, offering the capability to convert 'undruggable targets' into 'druggable targets.' In this article, Drug Target Review’s Izzy Wood interviewed Astellas’ Masahiko Hayakawa, Head of Targeted Protein Degradation, ...
-
ArticleThe promise of iPSC-based multi-cell therapeutics
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
-
ArticleThe evolution and promise of gene therapies
Dr David Baram from gene therapy company EmendoBio provides a snapshot of the history of therapeutic genetic engineering.
-
Whitepaperebook: Fluorescence polarization assays
This ebook outlines the basics of fluorescence polarization and discusses the advantages and limitations of FP-based biochemical assays.
-
Whitepaperebook: Choosing the right assay for PARP
This eBook describes different types of assays used to evaluate PARP activity and screening for specific inhibitors.
-
ArticleRNA processing in health and disease: challenges and opportunities of the field
In this interview, Sam Hasson, Senior Director at Rgenta Therapeutics, shares his journey in drug discovery, from graduate school to industry, and his current work developing small molecule therapeutics to target RNA processing. He discusses the challenges and opportunities in the field of RNA-centric drug discovery and highlights the potential ...
-
WhitepaperBrochure: Overcome roadblocks in your PROTAC characterizations with Dianthus
Learn how Dianthus resolves common challenges you face during the characterization of PROTAC binary and ternary complexes and the determination of cooperativity.
-
NewsNew method of designing drugs without side effects
Japanese researchers now reveal a new way of activating GPCR by triggering shape changes in the intracellular region of the receptor. This new process can help researchers design drugs with fewer or no side effects.
-
ArticlePromising human antibodies fighting SARS-CoV-2
Scientists have discovered that a vaccinated San Diego resident has produced antibodies that are effective against multiple variants of SARS-CoV-2, including Omicron. The research also identified three antibodies that can neutralise the virus, giving new insights into different binding mechanisms with the SARS-CoV-2 spike protein. The findings could help to ...
-
VideoVideo: Using luciferase reporter cell lines for HTS readouts
This video reviews the uses and advantages of reporter cell lines in the context of cellular research and drug discovery.
-
NewsNew gene linked to Malaria parasite's chloroquine resistance
Researchers have important implications for the ongoing fight against malaria, a disease that affects approximately 247 million individuals and causes over 619,000 deaths each year, predominantly among young children.
-
ArticleFramework for understanding cell organisation and variation
From a database of more than 200,000 high-resolution, three-dimensional images of human induced pluripotent stem cells, researchers have devised a model to quantify cell shape and internal organization. Susanne Rafelski, Deputy Director of the Allen Institute for Cell Science, revealed details of their study to Drug Target Review.
-
Articleebook: Advances In Cell Imaging and Retrieval
Unleash the power of drug discovery with this FREE ebook supported by Sartorius! Explore the limitless potential of CRISPR applications and single cell sequencing for drug discovery. Access exclusive insights from industry leaders and stay ahead of the curve with the latest trends. Don't miss out on this opportunity to ...
-
ArticleNew drug boosts foetal haemoglobin to fight sickle cell disease
Researchers are exploring the potential use of HDAC inhibitors, a group of drugs known for their capability to impede tumour cell division, to reduce the pain and damage associated with sickle cell disease. The drugs have shown initial evidence of reactivating the gene responsible for producing foetal haemoglobin, which cannot ...
-
Whitepaperebook: Quantitative Assays to Measure Ab Binding to Fc Receptors
This ebook summarizes the basics of Fc receptor function and discusses biochemical and cell-based assays that enable antibody optimization projects.
-
ArticleNew insight into BRCA2 gene mutations and cancer risk
A recent study from researchers at the University of California examines the BRCA2 gene, which plays a crucial role in repairing damaged DNA, and possible links with increased risk of breast and ovarian cancer.
-
ArticleChallenges and promises of personalised precision medicine
Drug Target Review’s Taylor Mixides exclusively interviews Neil Thomas, Partner and Head of Healthcare and Life Sciences for EMEA at Infosys Consulting, on personalised precision medicine, its advances, challenges and the future.
-
ArticleRevolutionary nanoparticles enable gene-editing in lungs
This article outlines the development of a new type of nanoparticle that can perform gene-editing in the lungs. Scientists from MIT and the University of Massachusetts Medical School have collaborated to create this Ribonucleic acid (RNA) delivery particles, which have the potential to revolutionise the treatment of lung diseases such ...
-
NewsRecombining drugs helps restore gene's ability to signal for death of leukaemia cells
US researchers find combination of chloroquine and venetoclax promotes cancer cell death in mouse models with acute myeloid leukaemia (AML).
-
NewsCannabinoids used in worms can help regulate various body systems
US study suggest worms could be a good research model for understanding the endocannabinoid system—and possibly developing better drugs.